CMV reactivation and disease progression in response to different GVHD prophylaxis methods
July 25th 2023The difference in utilizing cytomegalovirus reactivation outcomes while on posttransplantation cyclophosphamide vs other graft-vs-hose disease agents has led to a better understanding in long-term disease and reinfection rates.